CONTRAVISORY INVESTMENT MANAGEMENT, INC.
Position in DNLI — Denali Therapeutics Inc.
CIK 1365707
Norwell, MA
Position in DNLI
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$377,415
+$99,956 QoQ
Shares Held
14,674
+1.5% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#164
of 290 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CONTRAVISORY INVESTMENT MANAGEMENT, INC. holds $10,005,629 across 11 Biotechnology names. DNLI ranks #5 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,147 | $6,327,060 | |
| 2 | MRNA |
Moderna, Inc.
|
24,218 | $1,695,986 | |
| 3 | LGND |
Ligand Pharmaceuticals Inc
|
2,048 | $647,352 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
4,604 | $538,990 | |
| 5 | DNLI |
Denali Therapeutics Inc.
This page
|
14,674 | $377,415 | |
| 6 | BEAM |
Beam Therapeutics Inc.
|
9,899 | $339,733 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
171 | $32,024 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
288 | $21,450 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $377,415 | 14,674 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $277,459 | 14,451 | Shares | Sole | 2026-04-20 | |
| No filing history on record for this holder in this stock. | ||||||